via Ocular Surface Center Berlin
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.
“Our work has led to an effective and accessible solution called LiQD Cornea to treat corneal perforations without the need for transplantation,” said Griffith. She is also a full professor in the Department of Ophthalmology at Université de Montréal.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
LiQD Cornea
- Infectious disease expert says those over 50 should consider 4th COVID shot
With the latest fears of another surge in the fall, Dr. Liam Sullivan, an infectious disease specialist at Spectrum Health in Grand Rapids, says the CDC and FDA are considering authorizing a fourth ...
- Monkeypox outbreak | Experts call on WHO, governments for more action on infectious disease
While monkeypox is not as transmissible or dangerous as COVID-19, there needs to be clearer guidance on how a person infected with the disease should isolate, said the scientists ...
- Jon Hamm: Tom Cruise’s Enthusiasm Was Infectious On 'Top Gun: Maverick' Sets
Jon Hamm essays the role of Vice Admiral Beau ‘Cyclone’ Simpson, the distrusting superior of actor Tom Cruise's Maverick at the Top Gun institute. He talks about working with Cruise in the sequel to ...
- Your monkeypox questions answered by an infectious disease physician
And while it is spreading, how worried do we need to be? We spoke with infectious disease physician, Allison McGeer who breaks it all down with a reassuring outlook. Like us on Facebook to see similar ...
- Feds force JBS to make infectious disease plan
In a settlement with the Occupational Health and Safety Administration (OSHA), JBS has agreed to implement infectious disease plans at seven of it’s plants, including Grand Island.
Go deeper with Google Headlines on:
LiQD Cornea
Go deeper with Bing News on:
Corneal perforations
- Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent ...
